Study of Fecal Tumor M2-Pyruvate Kinase Level for Detection of Colorectal Cancer in Egyptian Adults

Authors

1 Internal Medicine, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt

2 Clinical Pathology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt

Abstract

Background: In terms of both incidence and mortality rates, colorectal cancer (CRC) ranks third globally. Aim and objectives: Identifying colorectal cancer(CRC) in adult Egyptian patients by evaluating the fecal M2-PK™ (ScheBo-test) level as a potential new biomarker. Patients and methods: From August 2022 through January 2024, one hundred subjects participated in this case-control study. Fifty patients admitted to Al-Azhar University Hospitals' internal medicine and nuclear medicine departments with colorectal cancer were included in the cases group. As a control group, we used 50 individuals who seemed to be in good health(i.e., no colorectal cancer and normal colonoscopy results). Results: The examined patients group with CRC had significantly increased levels of fecal M2-PK (p˂0.001). In the control group, the median fecal M2-PK level was 0.91U/ml, with a range of 0.12U/ml to 15.4U/ml. Case group fecal M2-PK levels ranged from 0.45U/ml to 71U/ml, with a median of 37U/ml. In this study, we found no statistically significant difference in the levels of fecal M2-PK between the sexes(P>0.05). Variable phases of Duke's disease were associated with significantly variable fecal M2-PK levels(P˂0.05). Conclusion: Despite numerous advancements in treatment, colorectal cancer continues to cause a great deal of suffering and death. Cancer cells often overexpress tumor M2-PK, a dimeric pyruvate kinase isoenzyme. Feces could be used to identify and quantify fecal M2-PK. Levels of fecal M2-PK correlated positively with TNM and Duke's stages.

Files

Share

How to cite

Statistics